Brief: Hansoh Pharmaceutical Says Xinyue (Inebilizumab Injection) Granted NMPA Approval For New Indication
27/03/2026 15:26
March 27 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: XINYUE (INEBILIZUMAB INJECTION) GRANTED NMPA APPROVAL FOR NEW INDICATION Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion